Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.

Date publication

décembre 2022

Journal

BMC gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36457080

Résumé

No study has performed a face-to-face comparison of biologics after the failure of the first anti-TNF agent in patients with Crohn's disease (CD). The aim of the study was to compare the efficacy of biologics in this setting.

Mots clés

Anti-TNF, Crohn’s disease, Second line, Treatment strategy, Ustekinumab, Vedolizumab

Référence

BMC Gastroenterol. 2022 12 1;22(1):498